Placenta growth factor inhibitors - Pipeline Insight, 2024

This “Placenta Growth Factor Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Placenta Growth Factor Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Placenta Growth Factor Inhibitors Understanding

Placenta Growth Factor Inhibitors: Overview

Placental Growth Factor (Pl GF) is a pleiotropic cytokine, similar to vascular endothelial growth factor (VEGF), which binds to its membrane bound receptor - fms tyrosine kinase 1 (Flt-1) to stimulateangiogenesis.

Function - The placental growth factor (PGF) gene is a protein-coding gene and a member of the vascular endothelial growth factor (VEGF) family. The PGF gene is expressed only in human umbilical vein endothelial cells (HUVE) and the placenta. PGF is ultimately associated with angiogenesis. Specifically, PGF plays a role in trophoblast growth and differentiation. Trophoblast cells, specifically extravillous trophoblast cells, are responsible for invading the uterine wall and the maternal spiral arteries. The extravillous trophoblast cells produce a blood vessel of larger diameter for the developing fetus that is independent of maternal vasoconstriction. This is essential for increased blood flow and reduced resistance.

Placenta Growth Factor Inhibitors - Pl GF plays a significant role in experimental CNV. Increased levels of PlGF have also been reported in eyes of patients with diabetes and interference with its receptor during oxygen-induced ischemic retinopathy (OIR) inhibits neovascularization. Therefore, targeting PlGF may be a promising strategy for treatment of eye diseases with a neovascular component including diabetic retinopathy, retinopathy of prematurity and exudativeAMD.

Placenta Growth Factor Inhibitors Emerging Drugs Chapters

This segment of the Placenta Growth Factor Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Placenta Growth Factor Inhibitors Emerging Drugs

FYB203: Bioeq FYB203 is a biosimilar of aflibercept (Eylea®) which was licensed by Santo Holding from Formycon AG in May 2015. Similarly to Lucentis®, Eylea® is prescribed for the treatment of neovascular age-related macular degeneration (neovascular AMD) and other serious eye conditions. Currently, it is in phase 3 of development stage for the treatment of Wet age-related maculardegeneration.

ABP 938: Amgen ABP 938 (aflibercept), a biosimilar candidate to EYLEA, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. Currently, it is in phase 3 of development stage for the treatment of Wet age-related maculardegeneration.

Placenta Growth Factor Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Placenta Growth Factor Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Placenta Growth Factor Inhibitors

There are approx. 15+ key companies which are developing the Placenta Growth Factor Inhibitors. The companies which have their Placenta Growth Factor Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Bioeq.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Placenta Growth Factor Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Placenta Growth Factor Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Placenta Growth Factor Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Placenta Growth Factor Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Placenta Growth Factor Inhibitors R&D. The therapies under development are focused on novel approaches for Placenta Growth Factor Inhibitors.

Placenta Growth Factor Inhibitors Report Insights

• Placenta Growth Factor Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Placenta Growth Factor Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Placenta Growth Factor Inhibitors drugs?
• How many Placenta Growth Factor Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Placenta Growth Factor Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Placenta Growth Factor Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Placenta Growth Factor Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Regeneron
• Ocular Therapeutix
• Alteogen
• 4D Molecular Therapeutics
• Celltrion
• Amgen
• Sam Chun Dang Pharm
• Samsung Bioepis
• Bioeq
• Prestige Biopharma
• Luye Pharma
• GlycoNex
• Momenta Pharmaceuticals
• Alteogen
• HEXAL
• Bayer

Key Products

• OTX-AFS
• ALT L9
• 4D 150
• CT-P42
• ABP 938
• SCD-411
• SB-15
• FYB203
• PBP 1602
• LY-09004
• SEA Aflibercept Biosimilar
• M-710
• REGN 910-3
• ALT L9
• SOK583A1
• BAY-865321

This product will be delivered within 1-3 business days.